Biotechnology Market News

Global Market for Biochips Expected to Reach .8 Million by 2013 ... - Reuters

Global Market for Biochips Expected to Reach .8 Million by 2013 ... Reuters - Nov 29, 2007 (www.bccresearch.com), the world market for biochip products will beworth some 1937.9 million in 2007, a figure that is expected toincrease to 115.6 ...

UPDATE 2-Interim data show Aranesp no help in breast cancer - Forbes

UPDATE 2-Interim data show Aranesp no help in breast cancer Forbes, NY - 12 minutes ago Shares in Amgen, the largest US biotechnology company by revenue, are down 19 percent so far this year. (Additional reporting by Bill Berkrot in New York) ...

Furniture Mart in Fort Pierce to go biotech - TCPalm

Furniture Mart in Fort Pierce to go biotech TCPalm, FL - 43 minutes ago ... Realty Inc of Fort Pierce and Boca Raton announced plans Friday to convert the Florida Furniture Mart in Fort Pierce into a biotechnology research park. ...

The Next Chinese Outsourcing Wave: Drug Development - CNNMoney.com

The Next Chinese Outsourcing Wave: Drug Development CNNMoney.com - 2 hours ago He then led genomics research at privately held Purdue Pharma before putting his knowledge to work building the China-based company. ...

Taking on India's new 'IT/BT' culture through films - Earthtimes

Taking on India's new 'IT/BT' culture through films Earthtimes, UK - 3 minutes ago 'It's about the growing influence of the IT/BT (information technology, biotechnology) culture and Westernisation on the minds of India,' says Naidu, 55, ...

The latest IQ debate - Blogger News Network

The latest IQ debate Blogger News Network - 1 hour ago If anything, the Eyferth study shows the central role of genetics in IQ. The study found that the children of black American gis and white women had similar ...

Government-Owned Inventions; Availability for Licensing - Trading Markets (press release)

Government-Owned Inventions; Availability for Licensing Trading Markets (press release), CA - 4 hours ago This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic ...

Astro Pak Corporation Acquires Oakley Specialized Services, Inc. - Reuters

Astro Pak Corporation Acquires Oakley Specialized Services, Inc. Reuters - 1 hour ago "Collectively, the two companies possess financial strength and an impressive list of pharmaceutical and biotechnology customers. ...

handbag horrors (Her Accessories)

I just recently received this email from my mom & decided to check it out: HANDBAGS a I never gave it a thought. Who would have thought? Have you [...]

biospace med Raises 8 Million in Venture Capital Funding - American Digital Networks (press release)

biospace med Raises 8 Million in Venture Capital Funding American Digital Networks (press release), MD - 1 hour ago ... over 80 years of cumulated experience in the life science industry and has a proven track record in biotechnology and medical technology investments. ...

Menstrual blood tapped as source of stem cells - MSNBC

Menstrual blood tapped as source of stem cells MSNBC - 1 hour ago Researchers from Medistem, a biotechnology firm in Tempe, Ariz., reported the discovery of the new stem cells, dubbed endometrial regenerative cells, ...

In quest of immortality, peace and happiness - The Daily Star

In quest of immortality, peace and happiness The Daily Star, Bangladesh - 1 hour ago Breakthroughs in genetics and pharmacy may lead us to the shores of immortality, in the far future. The frantic search of the Daoists for elixir had some ...

Biolog Initiates Launch of Its Revolutionary GEN III Microbial Identification System (Business Wire)

HAYWARD, Calif.--(BUSINESS WIRE)--Biolog, Inc. began the launch of its 3rd generation microbial ID system with the first public presentation detailing how the system

Bavarian Nordic Receives 5 Million Milestone Payment From HHS for Fulfilling Contract Milestones

WASHINGTON DC, November 30 /PRNewswire-FirstCall/ -- Bavarian Nordic has received permission from the Department of Health and Human Services (HHS) to invoice a milestone payment of 5 million as allowed under the RFP-3 contract* to manufacture and deliver 20 million doses of the company's, IMVAMUNE(R) next-generation smallpox vaccine candidate. HHS granted permission because the company fulfilled a number of significant milestones in the contract. The income will be recognised as revenue in the company's financial statements for 2007.

Anders Hedegaard, President & CEO of Bavarian Nordic, said, "We are very satisfied that we have fulfilled another significant milestone as agreed with the Department of Health and Human Services. With the already received and future payments, we have created a solid financial base for our further development."

In October 2007, Bavarian Nordic received an advance payment of 0 million from HHS as allowed under the contract. In addition to this amount and the current milestone payment, the company expects to receive an additional milestone payment of 5 million in 2007.

About the smallpox vaccine contract

In June 2007, HHS awarded Bavarian Nordic a BioShield contract to manufacture and deliver IMVAMUNE(R), a next-generation smallpox vaccine candidate to the strategic national stockpile. The contract calls for the registration of IMVAMUNE(R) as a safe and effective smallpox vaccine in healthy people, but in the event of a smallpox outbreak the vaccine would be recommended to protect people who have weakened immune systems.(1)

The five-year contract is valued at more than 00 million, with an option that if exercised, extends the value to .6 billion and the performance period of the contract. The contract option would allow the government to procure up to an additional 60 million doses of IMVAMUNE(R) and support additional clinical studies for extending the license to include the HIV-infected, pediatric, and geriatric populations.

Bavarian Nordic's contract is the first next-generation, or completely new product procured by HHS under the BioShield program. It is also is the first contract where HHS has utilized all of its existing and newly-acquired payment authorities (Advance Payment, Milestone Advance Payment, and Performance Based Payment) as granted under the Project BioShield Act (2004), The Pandemic and All-Hazards Preparedness Act (2006), and the FAR subpart 32.10.

Notes/References

* This project has been funded in whole with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100200700034C.

(1) http://www.hhs.gov/news/press/2007pres/06/pr20070604a.html About Bavarian Nordic

Bavarian Nordic, headquartered in Denmark, is a leading international biopharmaceutical company developing and producing innovative vaccines to prevent and treat infectious diseases and cancer.

In the U.S., Bavarian Nordic operates subsidiary companies, BN ImmunoTherapeutics, in Mountain View, California developing vaccines against cancers, and Bavarian Nordic Inc. in Washington, D.C. focused on business development, marketing, and government relations for the Bavarian Nordic Group. For more information on Bavarian Nordic visit: http://www.bavarian-nordic.com/

"Safe Harbour" Statement under the Private Securities Litigation Reform Act of 1995": Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. No "forward-looking statement" can be guaranteed, and actual results may differ materially from those projected. Bavarian Nordic undertakes no obligation to publicly update any "forward-looking statement", whether as a result of new information, future events, or otherwise. Additional information regarding risks and uncertainties is set forth in the current Annual Report and in Bavarian Nordic's periodic reports, if any, which we incorporate by reference.

Bavarian Nordic A/S

CONTACT: Elizabeth Dempsey Becker, Bavarian Nordic, Inc.,
1(202)536-1576

biotechcorp Acquires Licence For Nanotechnology Platform - Nanowerk LLC

biotechcorp Acquires Licence For Nanotechnology Platform Nanowerk LLC, HI - 59 minutes ago (Nanowerk News) Malaysian Biotechnology Corporation (biotechcorp) today announced its first technology acquisition by acquiring a worldwide licence to a ...

Berlin Heart Enrolls First Patient in US Multi-Center EXCOR(R) Pediatric VAD IDE Study

BERLIN, November 30 /PRNewswire/ -- Berlin Heart today announced the first patient enrolment in the prospective IDE study for its EXCOR(R) Paediatric VAD, a mechanical cardiac support system for critically ill Paediatric patients suffering from severe heart failure.

The multi-center IDE study is to evaluate the safety and probable benefit of using the EXCOR(R) Paediatric VAD to support Paediatric patients. The U.S. Food and Drug Administration granted conditional approval for the prospective IDE study to begin initially at 10 centers with 10 patients in May 2007.

The first patient in the study is an 8-year-old boy suffering from a congenital heart defect. The patient needed a biventricular assist device to support his weakened heart until a donor heart becomes available. The child had been transported from Texas to Arkansas Children's Hospital on an ECMO system (extra-corporeal membrane oxygenation) for the procedure.

On 27 November 2007 Dr. Michiaki Imamura, M.D., Ph.D., carried out the surgery that is reported to have gone well and without complications according to Dr. Robert Jaquiss, the Principal Investigator for the IDE study at Arkansas Children's Hospital. The patient is stable and currently in the ICU. Arkansas Children's Hospital has so far treated 13 patients with EXCOR(R) Paediatric, twelve of them under the compassionate use regulations.

Dr. Jaquiss commented: "We are very pleased the first EXCOR(R) Paediatric patient has been enrolled into the IDE study at our center. There is a great deal of interest in the medical community that this study proceeds quickly."

EXCOR(R) Paediatric has been designed as a bridge to transplantation for patients waiting for a suitable donor heart, but has also been used as a bridge to recovery when a patient's heart was able to recover and work on its own again. Unlike standard heart-lung machines, EXCOR(R) Paediatric has been used as a medium- to long-term support system, supporting failing hearts for up to several months.

Dr. Charles Fraser, M.D., the National Principal Investigator for the IDE study, congratulated the team at Arkansas Children's Hospital for proceeding with the first implant of the Berlin Heart EXCOR Paediatric VAD as part of the IDE study: "The initiation of this study represents a giant step forward in the care of children with critical heart failure. Those of us involved in this project are excited about the prospect of improved therapies for children in desperate need."

Dr. Rolf Kaese, CEO at Berlin Heart, commented: "Enrolling the first patient in the EXCOR(R) Paediatric IDE study marks a milestone and brings us one step closer toward obtaining HDE approval. This device fills a real void as it provides cardiac assist to the smallest patients for whom no real alternative exists."

About EXCOR(R) Paediatric

EXCOR(R) Paediatric is a pulsatile, pneumatically driven ventricular assist device and can be used to support one or both ventricles. EXCOR(R) Paediatric has been used in a total of 343 Paediatric patients ranging from newborns with 2 kg to teenagers with 90 kg body weight. The system has been used 118 times in North-America; with the FDA granting permission on a compassionate use basis.

About Berlin Heart

Berlin Heart is the only company that is able to provide a mid- to long-term ventricular assist device in the United States for Paediatric patients of every age and body size. The company manufactures pumps, cannulas, and external components for internal and external use to stabilise cardiac activity in acutely ill patients. Berlin Heart's products INCOR(R), EXCOR(R) and EXCOR(R) Paediatric are market leaders in their respective segments in Germany and in Europe. Berlin Heart Inc., the company's US subsidiary, was founded in 2005 and supports North-American centers under the FDA investigational study. Further product information is available from the company website: http://www.berlinheart.com/.

Contact: Linda Buerk, Berlin Heart GmbH, Phone: 49(0)30-8187-2650, Cell: 49(0)173-629-0803, Fax: 49(0)30-8187-22-2650, buerk@berlinheart.de.

Berlin Heart AG

CONTACT: Contact: Linda Buerk, Berlin Heart GmbH, Phone:
49(0)30-8187-2650, Cell: 49(0)173-629-0803, Fax: 49(0)30-8187-22-2650,
buerk@berlinheart.de.

Duke scientists: Genes are switched off before they are passed on - Asheville Citizen-Times

Duke scientists: Genes are switched off before they are passed on Asheville Citizen-Times, NC - 1 hour ago (AP/The Scientific Research Society; The Australian Genetics Resource Book) More intriguing, the work marks an important step in studying how our ...

BUYINS.NET: SBKC, VLCCF, DNAG, PTSG, NURMF, SNTO Have Been On ... - Trading Markets (press release)

BUYINS.NET: SBKC, VLCCF, DNAG, PTSG, NURMF, SNTO Have Been On ... Trading Markets (press release), CA - 1 hour ago In addition, it offers dnawitness product suite for the forensics market to determine genetic heritage from DNA samples obtained from crime scenes; ...

MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification Company to Report Interim Celgosivir 4-Week Viral Kinetics Study Data on Monday December 3, 2007

VANCOUVER and SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Thursday, December 13, 2007 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the second fiscal quarter ended October 31, 2007 and provide an update on company activities. To participate in the conference call, please dial 416-644-3418 or 1-800-732-1073. The call will be available for replay until December 27, 2007 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21255722 (followed by the number sign). The live and archived webcast can be accessed through the company's website at http://www.migenix.com/ for the next 90 days.

Additionally, the Company will report interim 4-week data from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection on Monday December 3, 2007.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com/.

"Jim DeMesa" James M. DeMesa, M.D. President & CEO

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com

MIGENIX Inc.

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233,
aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212)
825-3210, Theproteam@aol.com

Raven Announces Appointment of Michael Kranda as Chairman of the Board - PharmaLive.com (press release)

Raven Announces Appointment of Michael Kranda as Chairman of the Board PharmaLive.com (press release), PA - 31 minutes ago (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. ...

Raven Announces Appointment of Michael Kranda as Chairman of the Board

SOUTH SAN FRANCISCO, Calif., Nov. 30 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for treating cancer, today announced the appointment of Michael Kranda as chairman of the board. Mr. Kranda replaces Bill Young who remains on the Raven board as a director.

Mr. Kranda led life sciences venture investments as Managing Director for Vulcan Capital through 2006 and continues to consult for Vulcan. He sits on the board of directors of several companies including BiPar Sciences and PTC Therapeutics. Mr. Kranda was the chief executive officer of Oxford GlycoSciences (OGS) for six years, establishing the company as the leading proteomics platform-based drug discovery company. Prior to that, Mr. Kranda spent 12 years at Immunex (now Amgen) where he served as president and chief operating officer and director.

"We are delighted to have Michael's continuing leadership as board chair, and I look forward to working with him to advance our goals." said George F. Schreiner, M.D., Ph.D., Raven's chief executive officer.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com/) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, and ovarian cancer.

Raven biotechnologies, inc.

CONTACT: Stephen Worsley, Vice President, Business Development of Raven
biotechnologies, inc., sworsley@ravenbio.com, 1-650-624-2662; or Ellen Rose
of Availe Communication, 1-650-387-8746, for Raven biotechnologies, inc.

Web site: http://www.ravenbio.com/

Sanofi-Aventis would acquire biotech company if deal good - Forbes

Sanofi-Aventis would acquire biotech company if deal good Forbes, NY - 27 minutes ago ... with biotech companies as it aims to double or triple by 2012 the proportion of drugs it produces using biotechnology, research chief Marc Cluzel said. ...

The World Economic Forum Announces Technology Pioneers 2008: Mondobiotech Selected

BASEL, Switzerland, November 30 /PRNewswire/ -- The World Economic Forum today announced 39 visionary companies selected as Technology Pioneers 2008. Mondobiotech has been selected as one of these Technology Pioneers. The Technology Pioneers 2008 were nominated by the world's leading technology experts, including venture capitalists, technology companies, academics and media. The final selection from 273 nominees was made by a panel of leading technology experts appointed by the World Economic Forum. Technology Pioneers 2008 are invited to participate in the World Economic Forum Annual Meeting 2008 that will be held in Davos, Switzerland, from 23-27 January and in the Annual Meeting of the New Champions that will be held in Tianjin, People's Republic of China from 25-27 September 2008.

One of this year's Technology Pioneers is Mondobiotech, an independent, research engine biotech company focused on the development of treatment options for fatal and neglected rare diseases. It successfully develops human peptides to treat patients affected by rare diseases. This is done through its "search and development - S&D" method, access the global scientific know-how on potential therapeutics.

"This World Economic Forum Selection as a Technology Pioneer 2008 is an incredible honour for Mondobiotech and a validation of our unique business model," said Fabio Cavalli, CEO of Mondobiotech.

"As this is the first year a Swiss biotech receives this prestigious award, we are especially pleased to be granted this international recognition. This prize clearly supports our mission to change the world in healthcare and find the cure for an increasing number of the 7,000 neglected diseases in the near future."

Technology Pioneers are companies that have been identified as developing and applying highly transformational and innovative technologies in the areas of energy, biotechnology and health, and information technology. To be selected as a Technology Pioneer, a company must be involved in the development of life-changing technology innovation and have the potential for long-term impact on business and society. In addition, it must demonstrate visionary leadership, show all the signs of being a long-standing market leader - and its technology must be proven. Previous Technology Pioneers have included Business Objects, Cambridge Silicon Radio, Corel Corporation, Encore Software, Google, Mozilla Corporation and Napster.

The companies' products and services include identity management on the Internet, understanding of individuals' genetic information, robotic radiosurgery, pollution control materials, low-cost remote diagnosis solutions, virtual interface echnologies, wiki-based projects and next-generation business intelligence solutions.

Twenty-three of the Technology Pioneers 2008 are US-based companies. Israel and the United Kingdom each boast three; Sweden and Switzerland two each; Canada, France, Germany, India, the Netherlands and Russia, one each. Technology Pioneers are nominated in three main categories: Energy/Environment, Biotechnology/Health and Information Technology.

The entire list of Technology Pioneers and interviews with the CEOs of the selected companies can be found here: http://www.weforum.org/techpioneers/2008.

"This year the World Economic Forum received a record number of applications from companies around the world to become a Technology Pioneer. From a highly competitive field, we are extremely pleased to have a community that is using innovation and technology to dramatically affect the way society and business operate and doing so in a markedly collaborative manner. We are excited to welcome the Technology Pioneers class of 2008 to the larger community of the World Economic Forum and we are looking forward to the fruits that their collaboration will bring," said Peter Torreele, Managing Director of the World Economic Forum.

The selection criteria include:

1) Innovation. The company's technology must be truly innovative. A new version or repackaging of an already well-accepted technological solution does not qualify as an innovation. The innovation should be recent - not more than two years old. The company should invest significantly in R&D.

2) Potential Impact. The company's technology must have the potential to have a substantial long-term impact on business and society in the future.

3) Growth and Sustainability. The company should have all the signs of being a long-term market leader and should have well-formulated plans for future development and growth.

4) Proof of Concept. The company must have a product on the market or have proven practical applications of the technology. Companies in "stealth" mode and companies with untested ideas or models will not qualify.

5) Leadership. The company must have visionary leadership that plays a critical role in driving the company towards reaching its goals.

6) Status. The company must not currently be a Member of the World Economic Forum. This criterion applies to the parent company - thus wholly-owned subsidiaries of large firms are not eligible.

About Mondobiotech

Mondobiotech AG is a private Swissbiotech company founded in 2001 and headquartered in Switzerland. The company is focused on the development of treatment options for fatal and neglected rare diseases. Mondobiotech currently has 30 products in development for 30 indications, and is carrying out its "search and development" strategy to identify potential treatments for many other rare diseases. The company has out-licensed its lead product Aviptadil for use in Pulmonary Arterial Hypertension to Biogen Idec and Interferon-gamma for the treatment of IPF to Intermune Inc. The company has obtained 5 Orphan Medical Product Designation for Aviptadil in Europe and in the US, the last one granted in October 2007for the treatment of Sarcoidosis in the European Union.

About the World Economic Forum

The World Economic Forum is an independent international organization committed to improving the state of the world by engaging leaders in partnerships to shape global, regional and industry agendas.

Incorporated as a foundation in 1971, and based in Geneva, Switzerland, the World Economic Forum is impartial and not-for-profit; it is tied to no political, partisan or national interests. (http://www.weforum.org)

http://www.mondobiotech.com

Notes to Editors:

- Go to http://www.weforum.org/techpioneers/2008 for the entire list of Technology Pioneers and interviews with the CEOs of the selected companies. For more specific information, please e-mail: tech.pioneers@weforum.org.

- Download print-quality high resolution photographs of the CEOs of the selected companies at: http://www.pbase.com/forumweb/techpioneers2008

- Nominate a company to be a Technology Pioneer 2009 at: http://www.weforum.org/pdf/ techpioneers/nomination_form_2008.pdf . Deadline for submissions is May 2008.

Contact: Mondobiotech AG media@mondobiotech.com 41(0)-840-200-027

Mondobiotech AG

Contact: Mondobiotech AG, media@mondobiotech.com, 41(0)-840-200-027

Personalised genomics for everyone - PHG Foundation

Personalised genomics for everyone PHG Foundation, UK - 12 minutes ago Two companies have recently launched direct access whole genome scans, and more are planning to introduce similar services in early 2008. ...

NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria

HELSINGBORG, Sweden, November 30 /PRNewswire/ -- NOLabs AB, the Swedish medtech company developing innovative nitric oxide-containing medical devices based on the NitroSense(R) Technology, today reported that it has achieved another important milestone in the development of a new line of products for wounds infected by MRSA-bacteria. MRSA stands for Methicillin Resistant Staphylococcus aureus, a bacterium that is particularly troublesome in hospital-acquired infections due to its resistance to several traditional antibiotics.

In experiments performed at the Malmoe University Hospital in Sweden, researchers showed that NOLabs' technology has a promising ability to kill a wide range of pathogens, including MRSA.

According to the US Centers for Disease Control and Prevention 126,000 hospitalisations are related to MRSA and 19,000 deaths are associated with serious MRSA infections every year in U.S. hospitals. Patients at risk for infection with MRSA include those with severe disease, recent surgery or indwelling medical devices, such as urinary catheters.

Goran Beijer, CEO of NOLabs says: "The recent results show that we are on the right track towards products with an enormous potential globally. The anti-microbial effect of NO will be key in several products that will prevent and/or treat infection depending on dosing. We are now accelerating our development program and expect to have the first products on the market during 2008."

NOLabs' NitroSense(R) Technology assures controlled, local delivery of pure nitric oxide in a well-defined concentration range during a well-defined time period. The main areas are prevention of catheter related urinary tract infections, relief of neuropathic pain and wound care products with an anti-bacterial effect.

For more information please visit our home page: http://www.nolabs.com

NOLabs is a Swedish medtech company developing and marketing nitric oxide-containing medical devices for various medical applications. Nitric oxide is a natural substance, produced by the human body. Its physiological effects include the control of local blood supply and the protection against microbes. In particular, NOLabs focuses on prevention of infection and pain relief for patients suffering from diabetes-related complications such as chronic wounds and neuropathic pain. Another focus area is the prevention and treatment of catheter-associated urinary tract infections. NOLabs has developed the innovative, cost efficient and highly effective NitroSense(R) Technology with a significant potential to address serious health issues that impact the lives of over 100 million people.

Goran Beijer, E-mail goran.beijer@nolabs.com, Phone: 46-42-33-65-22; Susanne Goransson, E-mail: susanne.goransson@nolabs.com, Phone: 46-42-33-65-30.

NOLabs AB

Goran Beijer, E-mail goran.beijer@nolabs.com, Phone: 46-42-33-65-22; Susanne Goransson, E-mail: susanne.goransson@nolabs.com, Phone: 46-42-33-65-30.

Hiring controversy, state rules mean he will delay lobbying - Boston Globe

Hiring controversy, state rules mean he will delay lobbying Boston Globe, United States - 32 minutes ago But Robert K. Coughlin, the new president of the Massachusetts Biotechnology Council, said he won't discuss the bill at all. As a former state employee, ...

Fish research aims to help native population - The Daily Evergreen

Fish research aims to help native population The Daily Evergreen, WA - 26 minutes ago He said much of the research has focused on the genetics of domestication. For example, the controversy about the influence of hatcheries on native fish ...

Black identity, roots sought by lecturer - The Daily Collegian Online

Black identity, roots sought by lecturer The Daily Collegian Online, PA - 24 minutes ago "We were able to juxtapose historical evidence and genetic evidence," Gates said. "And we began to map where African-Americans came from."

Throne speech: Liberals just like Maple Leafs says Tory - National Post

Throne speech: Liberals just like Maple Leafs says Tory National Post, Canada - 1 hour ago If you're talking about information technology, digital media, financial services, insurance, biotechnology -- in those sectors we're growing two to three ...

Economic development grant awarded to partnership - Oil City Derrick

Economic development grant awarded to partnership Oil City Derrick, PA - 40 minutes ago The Biotechnology Business Development Center at Trinity Point will house the development center, Clarion University Small Business Development Center, ...